Company profile
Atossa Therapeutics, Inc.
NASDAQ: ATOS · Healthcare · Biotechnology
#1151 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
30DFH 29DQ 37GM 6SS 50
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$34.8M
Employees
16
as of 2026-08-21
Market cap
$25.8M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.8k$1.8k2015
Net income-$34.8M-$34.8M2025
Operating income-$37.1M-$37.1M2025
Total assets$47.6M$47.6M2025
Liabilities$8.3M$8.3M2025
Equity$39.4M$39.4M2025
Revenue trend
FY2012 – FY2015 · USD
FY12
FY12
FY13
FY14
FY15
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Atossa Therapeutics, Inc.’s revenue?
Atossa Therapeutics, Inc. booked $1.8k in FY2015 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -1977815.7% net margin.
Peers · Healthcare
Accelera Innovations, Inc——Instadose Pharma Corp.——Aibotics Inc.14DQuantum Medical Transport, Inc.——Health Discovery Corporation——ProText Mobility, Inc.——Neighbors
King →Key facts
CEOSteven C. Quay
SectorHealthcare
IndustryBiotechnology
HeadquartersSeattle, WA
ExchangeNASDAQ: ATOS
Employees16
IPO date2012-11-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.